CA2085873A1 - Traitement - Google Patents

Traitement

Info

Publication number: CA2085873A1
Authority: CA; Canada
Prior art keywords: histamine; receptor antagonist; treatment; antacid; gastric
Prior art date: 1990-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002085873A

Other languages

English (en)

Inventor

Adrian Francis Davis

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Beecham Group PLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-22

Filing date

1991-06-13

Publication date

1991-12-23

1990-06-22 Priority claimed from GB909013910A external-priority patent/GB9013910D0/en

1990-08-24 Priority claimed from GB909018676A external-priority patent/GB9018676D0/en

1991-06-13 Application filed by Individual filed Critical Individual

1991-12-23 Publication of CA2085873A1 publication Critical patent/CA2085873A1/fr

Status Abandoned legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 26
239000003485 histamine H2 receptor antagonist Substances 0.000 claims abstract description 48
229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims abstract description 43
229940069428 antacid Drugs 0.000 claims abstract description 31
239000003159 antacid agent Substances 0.000 claims abstract description 31
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 24
230000001458 anti-acid effect Effects 0.000 claims abstract description 20
208000012895 Gastric disease Diseases 0.000 claims abstract description 15
230000002496 gastric effect Effects 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 11
229960001380 cimetidine Drugs 0.000 claims description 11
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 11
210000001711 oxyntic cell Anatomy 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 9
102000005962 receptors Human genes 0.000 claims description 9
108020003175 receptors Proteins 0.000 claims description 9
230000003472 neutralizing effect Effects 0.000 claims description 8
230000009858 acid secretion Effects 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 4
239000011777 magnesium Substances 0.000 claims description 4
229910052749 magnesium Inorganic materials 0.000 claims description 4
229960000620 ranitidine Drugs 0.000 claims description 4
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
229960001596 famotidine Drugs 0.000 claims description 3
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 3
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
239000000347 magnesium hydroxide Substances 0.000 claims description 3
229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical class NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims description 2
239000005995 Aluminium silicate Substances 0.000 claims description 2
239000005711 Benzoic acid Chemical class 0.000 claims description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
208000025865 Ulcer Diseases 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
-1 alkali metal salts Chemical class 0.000 claims description 2
229910000147 aluminium phosphate Chemical class 0.000 claims description 2
229910000323 aluminium silicate Inorganic materials 0.000 claims description 2
PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 2
235000012211 aluminium silicate Nutrition 0.000 claims description 2
FIUBOPPLFYFRMW-UHFFFAOYSA-E aluminum;trimagnesium;carbonate;heptahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Al+3].[O-]C([O-])=O FIUBOPPLFYFRMW-UHFFFAOYSA-E 0.000 claims description 2
235000010233 benzoic acid Nutrition 0.000 claims description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
229940036348 bismuth carbonate Drugs 0.000 claims description 2
229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
235000010216 calcium carbonate Nutrition 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2
GMZOPRQQINFLPQ-UHFFFAOYSA-H dibismuth;tricarbonate Chemical compound [Bi+3].[Bi+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GMZOPRQQINFLPQ-UHFFFAOYSA-H 0.000 claims description 2
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
239000000395 magnesium oxide Substances 0.000 claims description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
239000000391 magnesium silicate Substances 0.000 claims description 2
229940099273 magnesium trisilicate Drugs 0.000 claims description 2
229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
235000011007 phosphoric acid Nutrition 0.000 claims description 2
239000004334 sorbic acid Chemical class 0.000 claims description 2
235000010199 sorbic acid Nutrition 0.000 claims description 2
229940075582 sorbic acid Drugs 0.000 claims description 2
239000011975 tartaric acid Chemical class 0.000 claims description 2
235000002906 tartaric acid Nutrition 0.000 claims description 2
231100000397 ulcer Toxicity 0.000 claims description 2
239000000499 gel Substances 0.000 claims 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
239000001095 magnesium carbonate Substances 0.000 claims 1
229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
235000014380 magnesium carbonate Nutrition 0.000 claims 1
235000012245 magnesium oxide Nutrition 0.000 claims 1
238000011260 co-administration Methods 0.000 abstract description 3
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 10
210000002784 stomach Anatomy 0.000 description 9
210000001519 tissue Anatomy 0.000 description 7
229960001340 histamine Drugs 0.000 description 6
230000009467 reduction Effects 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
230000009471 action Effects 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
102000003710 Histamine H2 Receptors Human genes 0.000 description 3
108090000050 Histamine H2 Receptors Proteins 0.000 description 3
208000008469 Peptic Ulcer Diseases 0.000 description 3
208000007107 Stomach Ulcer Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000029142 excretion Effects 0.000 description 3
238000007391 self-medication Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
208000028399 Critical Illness Diseases 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
206010020601 Hyperchlorhydria Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
201000000052 gastrinoma Diseases 0.000 description 2
229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
208000011906 peptic ulcer disease Diseases 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
208000004221 Multiple Trauma Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229960004872 nizatidine Drugs 0.000 description 1
SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
230000001175 peptic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002085873A 1990-06-22 1991-06-13 Traitement Abandoned CA2085873A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB909013910A GB9013910D0 (en)	1990-06-22	1990-06-22	Novel treatment
GB9013910.6		1990-06-22
GB909018676A GB9018676D0 (en)	1990-08-24	1990-08-24	Novel treatment
GB9018676.8		1990-08-24

Publications (1)

Publication Number	Publication Date
CA2085873A1 true CA2085873A1 (fr)	1991-12-23

Family

ID=26297238

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002085873A Abandoned CA2085873A1 (fr)	1990-06-22	1991-06-13	Traitement

Country Status (7)

Country	Link
EP (1)	EP0533770A1 (fr)
JP (1)	JPH05507695A (fr)
KR (1)	KR930701196A (fr)
AU (1)	AU7981391A (fr)
CA (1)	CA2085873A1 (fr)
IE (1)	IE912133A1 (fr)
WO (1)	WO1992000102A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2052698A1 (fr) *	1990-10-11	1992-04-12	Roger G. Berlin	Traitement des ulceres peptiques
CA2061520C (fr) *	1991-03-27	2003-04-22	Lawrence J. Daher	Systeme de delivrance accelerant l'effet et accroissant la puissance
GB9127150D0 (en) *	1991-12-20	1992-02-19	Smithkline Beecham Plc	Novel treatment
CA2110313C (fr) *	1992-12-01	2004-10-26	Edward John Roche	Compositions pharmaceutiques contenant un compose de guanidothiazole et antiacides
AU7255094A (en) *	1993-07-06	1995-02-06	Mcneil-Ppc, Inc.	H2 antagonist-antihistamine combinations
US5622980A (en) *	1993-08-17	1997-04-22	Applied Analytical Industries, Inc.	Oral compositions of H2-antagonists
ZA947553B (en) *	1993-09-30	1995-05-26	Glaxo Inc	Ranitidine and calcium carbonate pharmaceutical combination product
JP3587869B2 (ja) *	1993-12-16	2004-11-10	グラクソ・スミスクライン株式会社	医薬組成物
AU2912695A (en) *	1994-08-12	1996-03-07	Henry C Caldwell	Oral compositions of h2-antagonists
WO1998014198A1 (fr) *	1996-10-04	1998-04-09	Merck & Co., Inc.	Procedes et compositions pour la prevention et le traitement des brulures d'estomac
US5989588A (en) *	1996-10-04	1999-11-23	Merck & Co., Inc.	Methods and compositions for preventing and treating heartburn
EP1983827A4 (fr)	2006-02-01	2013-07-10	Stuart L Weg	Utilisation de compositions antifongiques pour traiter des conditions gastro-intestinales superieures
CA2984801A1 (fr)	2015-05-29	2016-12-08	Johnson & Johnson Consumer Inc.	Utilisation d'extrait d'agrumes biologiques a capacite antimicrobienne elevee en tant que systeme de conservation dans des liquides, des emulsions, des suspensions, des cremes et des anti-acides
MA42806A (fr)	2015-05-29	2018-07-25	Johnson & Johnson Consumer Inc	Utilisation d'un extrait d'agrume organique à haute capacité antimicrobienne et de xylitol en tant que système de conservation dans des liquides, des émulsions, des suspensions, des crèmes et des antiacides
WO2017091166A1 (fr)	2015-11-26	2017-06-01	Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş.	Compositions pharmaceutiques stables et leur procédé de préparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3710462A1 (de)	1987-03-30	1988-10-13	Heumann Pharma Gmbh & Co	Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
ATE73328T1 (de)	1987-05-08	1992-03-15	Smith Kline French Lab	Pharmazeutische zusammensetzungen.

1991
- 1991-06-13 WO PCT/GB1991/000953 patent/WO1992000102A1/fr not_active Ceased
- 1991-06-13 CA CA002085873A patent/CA2085873A1/fr not_active Abandoned
- 1991-06-13 KR KR1019920703296A patent/KR930701196A/ko not_active Withdrawn
- 1991-06-13 EP EP91911107A patent/EP0533770A1/fr not_active Withdrawn
- 1991-06-13 AU AU79813/91A patent/AU7981391A/en not_active Abandoned
- 1991-06-13 JP JP91510567A patent/JPH05507695A/ja active Pending
- 1991-06-20 IE IE213391A patent/IE912133A1/en unknown

Also Published As

Publication number	Publication date
EP0533770A1 (fr)	1993-03-31
KR930701196A (ko)	1993-06-11
WO1992000102A1 (fr)	1992-01-09
AU7981391A (en)	1992-01-23
JPH05507695A (ja)	1993-11-04
IE912133A1 (en)	1992-01-01

Legal Events

Date	Code	Title	Description
1998-06-15	FZDE	Dead

Publication	Publication Date	Title
US5656652A (en)	1997-08-12	Compositions containing histamine-H2 -receptor antagonists at low dosage
CA2085873A1 (fr)	1991-12-23	Traitement
AU705102B2 (en)	1999-05-13	Chewable tablets
AU627775B2 (en)	1992-09-03	Pharmaceutical compositions
US5976578A (en)	1999-11-02	Liquid antacid compositions
KR100238565B1 (ko)	2000-02-01	상부 위장관 통증을 치료하기 위한 섭취가능한 약학적 조성물
US4704278A (en)	1987-11-03	Fluidized magaldrate suspension
AU659422B2 (en)	1995-05-18	Composition containing antihistamine H2 receptor antagonists and bioadhesive material
ES2233932T3 (es)	2005-06-16	Composicion farmaceutica de antiacido.
JPH08512321A (ja)	1996-12-24	Ｈ▲下２▼拮抗剤−アルギネート−制酸剤の組合せ物
IL31858A (en)	1972-05-30	Concentrated liquid mixtures against acids
JPH0539219A (ja)	1993-02-19	胸やけ、胃痛または胃酸過多に関連した胃の不調の発泡性ｈ２ブロツカー製剤による治療
WO1995016446A1 (fr)	1995-06-22	Composes a base de ranitidine
AU2003204688B2 (en)	2008-04-10	Liquid antacid compositions
AU730391B2 (en)	2001-03-08	Liquid antacid compositions
MXPA98002968A (en)	1999-04-06	Antiaci liquid compositions
WO1996002262A2 (fr)	1996-02-01	Compositions pharmaceutiques pour le traitement de douleurs gastriques, comprenant des antiacides et des antagonistes des recepteurs h2 a l'histamine
HK1015264A (en)	1999-10-15	Chewable tablet